Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy
Yucai Wang(Mayo Clinic), Reem Karmali(Northwestern University), Mayur Narkhede(University of Alabama at Birmingham), Brian T. Hill(Cleveland Clinic), Ashlee Joseph, Irl Brian Greenwell(Medical University of South Carolina), Sabarish Ayyappan(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Stefan K. Barta(University of Pennsylvania), Craig A. Portell(University of Virginia), Lauren Banaszak(University of Wisconsin–Madison), Kami J. Maddocks(The Ohio State University), Amitkumar Mehta(University of Alabama at Birmingham), Georgio Pongas(University of Miami), Muhamad Alhaj Moustafa(Jacksonville College), Firas Baidoun(Mayo Clinic in Florida), Aung M. Tun(The University of Kansas Cancer Center), Drew G. Gerber(Duke Medical Center), Izidore S. Lossos(University of Miami), Taylor Brooks(Cleveland Clinic), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Marcus Messmer(Fox Chase Cancer Center), Jia Ruan(Cornell University), Rahul S. Bhansali(Hospital of the University of Pennsylvania), Zoey I. Harris(Mayo Clinic Hospital), Imran Nizamuddin(Northwestern University), Tamara K. Moyo(Carolinas Medical Center), Steven R. Hwang(Mayo Clinic), Alexander V. Stanisic(Northwestern University), Reid W. Merryman(Harvard University), Alexey V. Danilov(City of Hope), Brad S. Kahl(UW Health University Hospital), Christine E. Ryan(Dana-Farber Cancer Institute), Nilanjan Ghosh(Levine Cancer Institute), Natalie S. Grover(University of North Carolina at Chapel Hill), Patrick M. Reagan(University of Rochester), Arash Velayati(National Institutes of Health), Preetesh Jain(The University of Texas MD Anderson Cancer Center), Brian K. Link(University of Iowa), Priyanka A. Pophali(University of Wisconsin–Madison), Anita Kumar(Memorial Sloan Kettering Cancer Center), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Michael Wang(St. Joseph Health System), Melissa C. Larson(Mayo Clinic), Philip Young(University of Virginia), Anthony C. Stack(Fox Chase Cancer Center), Nazneen B. Khan(University of North Carolina at Chapel Hill), Jacob Anna(University of Colorado Anschutz Medical Campus), Christine McCarthy(City Of Hope National Medical Center), Manali Kamdar(University of Colorado Cancer Center)
Cited by 10
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k